Albert Ing, MD
Cardiovascular Disease · Kaneohe, HINPI 1730144494
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 373 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,816 and has fallen 56.8% since, to $785 in 2025.
Across 373 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Bayer$1K
- AstraZeneca$1K
- Boehringer Ingelheim$866
- Johnson & Johnson$714
- Merck$485
- plus $2K from 24 others
What the payments were for
- Food & beverage$8,09997%
- Education$2253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 77 | $1,592 |
| Bayer | 50 | $1,219 |
| AstraZeneca | 46 | $1,088 |
| Boehringer Ingelheim | 34 | $866 |
| Johnson & Johnson | 43 | $714 |
| Merck | 22 | $485 |
| Lexicon Pharmaceuticals, Inc. | 24 | $361 |
| Pfizer | 10 | $265 |
| Abbott | 7 | $256 |
| Irhythm Technologies, Inc. | 8 | $198 |
| Biotronik Inc. | 5 | $169 |
| E.r. Squibb & Sons, L.L.C. | 8 | $153 |
| Baxter Healthcare | 9 | $152 |
| Amgen | 2 | $136 |
| Astellas Pharma US Inc | 2 | $118 |
| Novartis | 6 | $110 |
| Alnylam Pharmaceuticals Inc. | 3 | $61 |
| Esperion Therapeutics, Inc. | 3 | $55 |
| Aurinia Pharma U.S., Inc. | 1 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $36 |
| Novo Nordisk | 1 | $28 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| Boston Scientific | 1 | $27 |
| Philips North America LLC | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Abiomed | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,324 in reported general payments places this provider in the 80th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 291 | $379,217 |
| JardianceEmpagliflozin | 213 | $288,934 |
| XareltoRivaroxaban | 204 | $257,137 |
| EntrestoSacubitril/Valsartan | 144 | $195,769 |
| BrilintaTicagrelor | 184 | $191,719 |
| FarxigaDapagliflozin Propanediol | 144 | $179,896 |
| InpefaSotagliflozin | 77 | $121,645 |
| Atorvastatin Calcium | 558 | $16,300 |
| OzempicSemaglutide | 12 | $11,406 |
| Metoprolol Succinate | 427 | $6,501 |
| ClopidogrelClopidogrel Bisulfate | 249 | $5,963 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $4,696 |
| Ranolazine ErRanolazine | 41 | $4,659 |
| Losartan Potassium | 251 | $3,373 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 64 | $2,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $265 | $379,217291 claims |
| AstraZenecaBrilinta, Farxiga | $1,088 | $371,615328 claims |
| Boehringer IngelheimJardiance | $866 | $288,934213 claims |
| Johnson & JohnsonXarelto | $714 | $257,137204 claims |
| NovartisEntresto | $110 | $195,769144 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $361 | $121,64577 claims |
| Novo NordiskOzempic | $28 | $11,40612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 73 cardiovascular disease providers in Hawaii.
Other cardiovascular disease in Kaneohe
- Ryan SmithKaneohe$125K
- Dipanjan BanerjeeHonolulu$331K
- Ramy BadawiKailua$78K
- Joana MagnoHonolulu$23K
- Hingson ChunHonolulu$23K
- Sonny WongKailua$18K
- William DangHonolulu$16K
- Erin DreessensTripler Amc$14K
- Edward ShenHonolulu$12K
- Se Kon WonHonolulu$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.